Thought Inc News Today

Research Analysts’ downgrades for Tuesday, May 31st: Adverum Biotechnologies (NASDAQ:ADVM) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable […]

AgileThought (NASDAQ:AGIL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday, Zacks.com reports. According to Zacks, “AgileThought Inc. is a provider of digital transformation services, custom software development and next-generation technologies. It serves architects, developers, data scientists, engineers, transformation consultants, automation […]

Investment Analysts’ downgrades for Monday, May 9th: Addex Therapeutics (NASDAQ:ADXN) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Addex Therapeutics Ltd is a clinical-stage pharmaceutical company. It is focused on the development and commercialization of small molecule drugs for neurological disorders. The company’s lead […]

AgileThought (NASDAQ:AGIL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday, Zacks.com reports. According to Zacks, “AgileThought Inc. is a provider of digital transformation services, custom software development and next-generation technologies. It serves architects, developers, data scientists, engineers, transformation consultants, automation […]

AgileThought announced its public offering pricing of Class A Common stock of about 3,560,710 shares priced at $7 per share. Aggregate gross profits are expected to hit the range of $25 million